Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Polycythemia Vera 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Thrombocythemia, Essential 5Carcinoma, Hepatocellular 4Neoplasms 3Melanoma 3Skin Neoplasms 2Philadelphia Chromosome 2Neoplasm Metastasis 2Myeloproliferative Disorders 2Leukemia 2Hepatitis C, Chronic 2Carcinoma, Squamous Cell 2Brain Neoplasms 2Solid Cancers 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasm, Residual 1Neoplasm of Uncertain Malignant Potential 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Influenza, Human 1Infections 1Hepatitis C 1Hepatitis B, Chronic 1Hemangiosarcoma 1Glioma 1Colonic Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Trimethoprim, Sulfamethoxazole Drug Combination 9Ciprofloxacin 7Voriconazole 5Caspofungin 4Amoxicillin-Potassium Clavulanate Combination 4gamma-Globulins 3Vancomycin 3Fluconazole 3Filgrastim 3Daptomycin 3Antibiotic Prophylaxis 3plerixafor 2liposomal amphotericin B 2Trimethoprim 2Therapeutics 2Sulfamethoxazole 2Saline Solution 2Ribavirin 2Polymerase Chain Reaction 2Peripheral Blood Stem Cell Transplantation 2Pentetic Acid 2Moxifloxacin 2Melphalan 2Levofloxacin 2Itraconazole 2Immunoglobulins, Intravenous 2Granulocyte Colony-Stimulating Factor 2Ethanol 2Cyclophosphamide 2Cefazolin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Infections × peginterferon alfa-2a × Clear all
NCT01821963 2020-09-24

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

M.D. Anderson Cancer Center

Phase 3 Terminated
1 enrolled 3 charts
Gastrointestinal

Hepatitis C, Carcinoma, Hepatocellular, Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡